{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:39:59Z","timestamp":1793021999669,"version":"4.5.0"},"reference-count":37,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate functional and anatomical outcomes after intravitreal dexamethasone implant (DEXI) in macular edema secondary to retinal vein occlusion (ME-RVO), comparing treatment-na\u00efve eyes with early-switch (ES) and late-switch (LS) eyes previously treated with anti-VEGF, to explore the optimal therapeutic window for switching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective real-world study including 71 eyes with ME-RVO treated with DEXI and followed for 12 months. Patients were classified as na\u00efve (no prior intravitreal therapy), ES (\u22643 anti-VEGF injections before switching), and LS (&gt;3 anti-VEGF injections before switching). Functional outcomes were assessed by best-corrected visual acuity (BCVA), and anatomical outcomes by central macular thickness (CMT) using spectral-domain optical coherence tomography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BCVA improved significantly at month 2 in treatment-na\u00efve and ES eyes (p\u2009&lt;\u20090.05), whereas no significant change was observed in LS eyes. A\u2009\u2265\u20092-line gain occurred in 50% of na\u00efve eyes, markedly higher than in previously treated eyes. Na\u00efve patients maintained functional and anatomical improvement throughout follow-up. All groups demonstrated an early reduction in CMT at month 2 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Multivariate analysis identified baseline BCVA, but not switching timing, as the main predictor of functional improvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While DEXI improved anatomical outcomes across all subgroups, functional recovery was more frequently observed in na\u00efve and ES eyes. However, baseline BCVA emerged as the main independent determinant of functional response, suggesting that visual outcomes are primarily driven by initial visual status rather than switching timing. By including a na\u00efve comparison group, this study provides novel insights into the management of ME-RVO in patients with suboptimal anti-VEGF response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721261461913","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:00:09Z","timestamp":1781856009000},"page":"1714-1722","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of na\u00efve, early switch and late switch eyes treated with dexamethasone intravitreal implant for retinal vein occlusion"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6310-3006","authenticated-orcid":false,"given":"Olga","family":"Diego-Navarro","sequence":"first","affiliation":[{"name":"University Hospital Complex of Albacete, Ophthalmology Department, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5433-5880","authenticated-orcid":false,"given":"Sergio","family":"Copete","sequence":"additional","affiliation":[{"name":"University Hospital Complex of Albacete, Ophthalmology Department, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4788-9850","authenticated-orcid":false,"given":"Almudena","family":"Moreno-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"University Hospital Complex of Albacete, Ophthalmology Department, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8294-7844","authenticated-orcid":false,"given":"Cristina","family":"Blanco-Marchite","sequence":"additional","affiliation":[{"name":"University Hospital Complex of Albacete, Ophthalmology Department, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206916"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002472"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02007-4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000502041"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.07.017"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2018.04.005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S351683"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14621"},{"key":"e_1_3_2_10_2","first-page":"1353","article-title":"Predictive value of OCT biomarkers for visual acuity outcomes in retinal vein occlusion","volume":"101","author":"Mylonas G","year":"2017","unstructured":"Mylonas G, Sacu S, Simader C, et al. Predictive value of OCT biomarkers for visual acuity outcomes in retinal vein occlusion. Br J Ophthalmol 2017; 101: 1353\u20131360.","journal-title":"Br J Ophthalmol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01702-y"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v19i3.13531"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.05.014"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.028"},{"key":"e_1_3_2_15_2","first-page":"777","article-title":"Efficacy and safety of dexamethasone implant for macular edema following retinal vein occlusion in a real-life setting","volume":"255","author":"Malcl\u00e8s A","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, et al. Efficacy and safety of dexamethasone implant for macular edema following retinal vein occlusion in a real-life setting. Graefes Arch Clin Exp Ophthalmol. 2017;255:777\u2013785.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.951666"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2017.31.2.108"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15040439"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175006"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.03.006"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2305361"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3394-y"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3831-6"},{"key":"e_1_3_2_24_2","first-page":"1849","article-title":"Outcomes after switching to intravitreal corticosteroids in anti-VEGF\u2013refractory ME-RVO","volume":"39","author":"Omar A","year":"2019","unstructured":"Omar A, Bressler SB, Bressler NM, et al. Outcomes after switching to intravitreal corticosteroids in anti-VEGF\u2013refractory ME-RVO. Int Ophthalmol 2019; 39: 1849\u20131858.","journal-title":"Int Ophthalmol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5831682","article-title":"Switch of intravitreal therapy for macular edema secondary to retinal vein occlusion from anti-VEGF to dexamethasone implant and vice versa","volume":"2017","author":"Pielen A","year":"2017","unstructured":"Pielen A, B\u00fchler AD, Heinzelmann SU, et al. Switch of intravitreal therapy for macular edema secondary to retinal vein occlusion from anti-VEGF to dexamethasone implant and vice versa. J Ophthalmol 2017; 2017: 5831682.","journal-title":"J Ophthalmol"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-2947-9"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000686"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120978355"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0012"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2019.1614020"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000473864"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000335047"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.118497"},{"key":"e_1_3_2_34_2","first-page":"2760","article-title":"Microstructural OCT changes correlated with vision in retinal vein occlusion","volume":"120","author":"Kang JW","year":"2013","unstructured":"Kang JW, Yoo R, Jo YJ, et al. Microstructural OCT changes correlated with vision in retinal vein occlusion. Ophthalmology 2013; 120: 2760\u20132767.","journal-title":"Ophthalmology"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.06.002"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000598"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1110166"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15066"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721261461913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721261461913","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721261461913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:10:57Z","timestamp":1793020257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721261461913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/11206721261461913"],"URL":"https:\/\/doi.org\/10.1177\/11206721261461913","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}